# A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

> **NCT06377228** · PHASE1 · WITHDRAWN · sponsor: **Takeda**

## Conditions studied

- Refractory Lupus Nephritis
- Refractory Systemic Sclerosis

## Interventions

- **BIOLOGICAL:** TAK-007
- **DRUG:** Chemotherapy Agents

## Key facts

- **NCT ID:** NCT06377228
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-13
- **Primary completion:** 2030-09-02
- **Final completion:** 2030-09-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision (no safety concerns)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06377228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06377228, "A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06377228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*